Navigation Links
Tiens Biotech Group (USA) Reports First Quarter Results
Date:5/15/2008

NEW YORK, May 15 /Xinhua-PRNewswire/ -- Tiens Biotech Group (USA), Inc. (the ''Company'' or ''Tiens''), (Amex: TBV), http://www.tiens-bio.com , announced financial results for the first quarter ended March 31, 2008.

Revenue for the first quarter of 2008 was $12.8 million compared to $16.2 million for the first quarter of 2007.

Net income for the first quarter of 2008 was $3.6 million, or $0.05 per share, compared to net income of $6.5 million, or $0.09 per share for the first quarter of 2007.

Revenue by Region

For the first quarter of 2008, revenue in China was $6.1 million compared to $7.2 million for the first quarter of 2007. Sales in China reflect the continued uncertainty regarding the effect of direct selling regulations and the timing of the direct selling license application process and approval. The application of Tianshi Engineering for a direct selling license in China is still pending and until the application is approved, Tianshi Engineering will continue to sell Tiens' products through its branches, affiliated companies and chain stores in China.

For the first quarter of 2008, international revenue was $6.7 million, compared to $9.0 million for the first quarter of 2007.

The change in international sales reflects China's General Administration of Quality Supervision, Inspection and Quarantine's (AQSIQ) ongoing national campaign in China against unsafe food and substandard products. As a result of this campaign by the AQSIQ, there has been a general slow-down and backlog of export clearances for Chinese food products. As a result of these delays, Tiens' international affiliates were not able to purchase sufficient quantities of its p RATE CHANGES ON CASH 2,153,552 509,087

INCREASE IN CASH 4,078,981 (2,337,049)

CASH, beginning of year 54,081,848 55,214,540

CASH, end of year $ 58,160,829 $ 52,877,491

Supplemental disclosures of cash

flow information

Cash paid during the year for:

Interest (net of amount

capitalized) $ -- $ --

Income taxes $ 455,480 $ 700,941

Note 1.

On December 20, 2007, the Company's subsidiary, Tianshi International Holdings Group Ltd (''Tianshi Holdings''), entered into a Sale and Purchase Agreement with Tianshi International Investment Group Co., Ltd. (''Tianshi Investment''). Pursuant to the Sale and Purchase Agreement, Tianshi Holdings agreed to buy all of the registered share capital of Tianjin Tiens Life Resources Co., Ltd. (''Life Resources'') for $64.2 million. The closing of the transaction was subject to government approval of transfer of all of the share capital of Life Resources to Tianshi Holdings. On March 13, 2008, the Chinese government approved the transfer. As Tianshi Holdings and Life Resources were under common control by Jinyuan Li before the combination, the combination was treated for accounting purposes as a pooling of interests. The balance sheet of the Company at December 31, 2007 and comparative interim financial statements for the corresponding periods of the preceding fiscal year were adjusted as if Life Resources had been combined before January 1, 2007.

TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES

REVENUE BY REGION

Three months

ended March 31,

2008 2007 Change

China $6,105,779 $7,210,301 -15.3%

International $6,715,042 $9,026,488 -25.6%

Total $12,820,821 $16,236,789 -21.0%

For more information, please contact:

Investor Relations

Tiens Biotech Group (USA), Inc.

Tel: +86-22-8213-7915

Fax: +86-22-8213-7667

Email: investor@tiens-bio.com

Web: http://www.tiens-bio.com

Carl Hymans

G. S. Schwartz & Co.

Tel: +1-212-725-4500

Fax: +1-212-725-9188

Email: carlh@schwartz.com

roducts to meet their demand. However, it is important to note that to date, no problems have been identified with any of Tiens' products. The campaign, which began in August 2007, was originally scheduled to finish at the end of 2007, is currently scheduled to continue throughout 2008.

Other Highlights

Cost of sales for the first quarter of 2008 was $4.0 million compared to $4.4 million for the same period in 2007. This decrease was primarily due to the decrease in sales revenue. The decrease in cost of sales was not in line with the decrease in revenue due to increases in the cost of our raw materials, and a strong remenbi compared to the dollar.

Gross profit for the first quarter of 2008 was $8.8 million compared to $11.8 million for the first quarter of 2007. The gross profit margin for the first quarter of 2008 was 68.5%, compared to 72.7% for the first quarter of 2007. The decreases reflect the aforementioned cost of raw materials which increased while the price at which products were sold remained constant.

Selling, general and administrative expenses were $3.2 million for the first quarter of 2008 and 2007. The selling and administrative expenses as a percentage of sales was 25.3% for the first quarter of 2008 compared to 20.1% for the same period in 2007. This increase reflects the fixed costs associated with selling, general and administrative expenses and the decline in revenue.

As of March 31, 2008, Tiens had $82.3 million of retained earnings and total shareholders' equity of $121.0 million.

Jinyuan Li, Chairman, President and CEO of Tiens, said, ''We continue to face the challenges of the current direct selling environment in China and delays in exporting our products internationally. Our high quality products have remained beyond reproach by the national campaign in China to prevent the export of unsafe products. We see future opportunities including the development of new products and enhancing our current manufacturing capabilities as part of our strategic initiatives to best position Tiens for long term domesic and international growth.''

About Tiens Biotech Group (USA), Inc. ( http://www.tiens-bio.com )

Tiens Biotech Group (USA), Inc. (AMEX: TBV) conducts its business operations from Tianjin, People's Republic of China. Tiens primarily engages in the research, development, manufacturing, and marketing of nutrition supplement products, including wellness products and dietary nutrition supplement products, and personal care products.

Tiens derives its revenues principally from product sales to affiliated companies in China and internationally in 52 countries. Since its establishment, Tiens has developed and produced 33 nutrition supplements, which include wellness products and dietary supplements. Tiens develops its products at its own product research and development center, which employs highly qualified professionals in the fields of pharmacology, biology, chemistry and fine chemistry. Tiens has obtained all required certificates and approvals from government regulatory agencies to manufacture and sell its products in China.

In China, Tiens conducts the marketing and sales of its products through its affiliated company, Tianshi Engineering. Tianshi Engineering markets and sells Tiens' products in China through chain stores, domestic affiliated companies, and its 100 branches. Outside of China, Tiens sells its products to affiliated companies in 52 countries who in turn sell through an extensive direct sales force, or multi-level marketing sales force. The Company's direct sales marketing program is subject to governmental regulation in each of these countries.

Certain statements in this press release constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Such forward-looking statements are not necessarily indicative of future financial results, and may involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to: (i) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) whether the Company continues to experience delays in the export clearance of its products; (v) whether Tianshi Engineering, the Company's affiliate which sells its products in China, obtains a direct selling license in China; and (vi) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at http://www.sec.gov under ''Search for Company Filings.''

--Tables Follow--

TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME

FOR THE THREE MONTHS ENDED MARCH 31, 2008 AND 2007

2007

2008 As Adjusted

(Unaudited) (See Note 1)

REVENUE - RELATED PARTIES $ 12,820,821 $ 16,236,789

COST OF SALES - RELATED PARTIES 4,040,060 4,435,599

GROSS PROFIT 8,780,761 11,801,190

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES 3,247,199 3,264,907

INCOME FROM OPERATIONS 5,533,562 8,536,283

(Interest expense) (52,584) (105,222)

Interest income 237,332 629,913

Other expense income, net 259,423 (74,479)

OTHER EXPENSE INCOME, NET 444,171 450,212

INCOME BEFORE PROVISION FOR INCOME TAXES

AND MINORITY INTEREST 5,977,733 8,986,495

PROVISION FOR INCOME TAXES 1,480,394 711,010

INCOME BEFORE MINORITY INTEREST 4,497,339 8,275,485

MINORITY INTEREST 888,437 1,753,218

NET INCOME 3,608,902 6,522,267

OTHER COMPREHENSIVE INCOME

Foreign currency translation adjustment 4,423,860 1,389,352

COMPREHENSIVE INCOME $ 8,032,762 $ 7,911,619

EARNINGS PER SHARE, BASIC AND DILUTED $ 0.05 $ 0.09

WEIGHTED AVERAGE NUMBER OF SHARES 71,333,586 71,333,586

TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

AS OF MARCH 31, 2008 AND DECEMBER 31, 2007

A S S E T S

March 31, December 31,

2008 2007

(unaudited) As Adjusted

(See Note 1)

CURRENT ASSETS:

Cash $ 58,160,829 $ 54,081,848

Accounts receivable, trade - related

parties, net of allowance for

doubtful accounts of $59,412 and

$71,700 as of March 31, 2008 and

December 31, 2007, respectively 11,822,927 14,268,229

Accounts receivable, trade - third

parties --- 104,398

Inventories 6,649,229 5,949,963

Other receivables 851,436 1,068,343

Other receivables - related parties 12,744,336 13,887,138

Employee advances 118,583 65,901

Prepaid expenses 533,330 623,638

Total current assets 90,880,670 90,049,458

PROPERTY, PLANT AND EQUIPMENT, net 16,135,968 16,071,900

OTHER ASSETS:

Construction in progress 46,332,756 39,792,774

Construction deposits 1,036,204 1,089,216

Intangible assets, net 9,576,608 9,246,879

Other assets 5,569,703 5,301,847

Total other assets 62,515,271 55,430,716

Total assets $ 169,531,909 $ 161,552,074

TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

AS OF MARCH 31, 2008 AND DECEMBER 31, 2007

L I A B I L I T I E S A N D S H A R E H O L D E R S' E Q U I T Y

March 31, December 31,

2008 2007

As Adjusted

(Unaudited) (See Note 1)

CURRENT LIABILITIES:

Accounts payable $ 4,085,944 $ 4,070,906

Advances from customers - related

parties 1,772,749 1,700,838

Wages and benefits payable 1,096,302 1,250,685

Other taxes payable 175,324 536,819

Income taxes payable 1,740,778 665,736

Contractor deposits 329,665 595,128

Contractor payables 8,666,740 7,820,285

Other Payables 1,342,448 1,133,539

Other payables - related parties 4,885,515 7,938,205

Dividend payable to minority

interest 5,106,666 4,902,629

Current portion of long term debt,

related party 2,130,000 2,130,000

Total current liabilities 31,302,131 32,744,760

NON-CURRENT LIABILITIES:

Long term debt, net of current

portion, related party 4,267,742 4,267,742

Other payables-non-current 560,526 538,130

Deferred income 5098,771 4,895,049

Total non-current liabilities 9,927,039 9,700,921

Total liabilities 41,229,170 42,445,681

MINORITY INTEREST 7,307,647 6,144,063

SHAREHOLDERS' EQUITY:

Common stock, $0.001 par value,

250,000,000 shares authorized,

71,333,586 issued and outstanding,

respectively 71,334 71,334

Paid-in-capital 8,842,009 8,842,009

Statutory reserves 9,420,783 9,420,783

Retained earnings 82,277,062 78,668,160

Accumulated other comprehensive

income 20,383,904 15,590,044

Total shareholders' equity 120,995,092 112,962,330

Total liabilities and

shareholders' equity $ 169,531,909 $161,552,074

TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31, 2008 AND 2007

Three months ended March 31

2008 2007

As Adjusted

(Unaudited) (See Note 1)

CASH FLOWS FROM OPERATING

ACTIVITIES:

Net income $ 3,608,902 $ 6,522,267

Adjustments to reconcile net

income to cash provided by

(used in) operating activities:

Provision for doubtful accounts (12,288) (2,819)

Minority interest 888,437 1,753,218

Depreciation 683,155 700,148

Amortization 60,894 58,597

Interest income (53,159) (405,211)

(Gain) loss on sale of assets (8,431) --

(Increase) decrease in assets:

Accounts receivable, trade -

related parties (3,914,933) (3,633,193)

Accounts receivable, trade -

third parties 106,413 --

Other receivables 255,386 (16,831)

Other receivables - related parties (198,638) 599,858

Inventories (441,968) 653,771

Employee advances (48,871) 18,164

Prepaid expense 112,341 (107,382)

Increase (decrease) in liabilities:

Accounts payable (169,891) (902,938)

Advances from customers -

related parties 1,102 (43,110)

Wages and benefits payable (200,580) (11,718)

Other taxes payable 649,299 398,094

Other payables 158,270 (152,536)

Other payables - related parties 125,300 (297,067)

Net cash provided by

operating activities 1,600,740 5,131,312

CASH FLOWS FROM INVESTING

ACTIVITIES:

Loan to (from) related parties 1,403,831 (1,032,080)

Acquisition of intangible assets -- (127,996)

Construction deposits 96,237 207,822

Contractor deposits (284,016) --

Addition to construction in progress (4,257,203) (5,926,815)

Purchase of equipment and automobiles (123,344) (296,416)

Net cash used in investing

activities (3,164,495) (7,175,485)

CASH FLOWS FROM FINANCING ACTIVITIES:

Loan from related parties 3,489,184 374,129

Increase in registered share capital -- 5,500,010

Payments to minority interest shareholder -- (6,676,102)

Net cash provided by (used

in) financing activities 3,489,184 (801,963)

EFFECT OF EXCHANGE
'/>"/>

SOURCE Tiens Biotech Group (USA), Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. KGI 2008 Commencement Features First PhD Graduate, Biotech Painting
2. ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses From Bayer Healthcare
3. Genetic Engineering and Biotechnology News reports on early ADMET use
4. China Medicine Corporation Selected to Represent Biotechnology Industry of Guangzhou City at 2008 Annual BIO International Convention
5. PCMA Response to New York Times Article on Biotech Medicine Costs
6. PCMA: Skyrocketing Biotech Prices Challenge Employers, Consumers
7. Rising Australian biotech stars set to connect on the world stage
8. Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
9. VCU Massey Cancer Center to partner with Israeli biotech firm
10. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
11. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... with extensive sequencing and genomics experience, as Vice President of North American Capital Sales ... be responsible for leading the sales team in the commercialization of the HTG EdgeSeq ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology: